FDA Backpedals on Aduhelm Approval, Now Says Only Early Alzheimer’s Patients Should Get It

The Food and Drug Administration is altering its recent and controversial approval of a new drug for Alzheimer’s disease. The agency is now recommending that the drug, called Aduhelm and developed by Biogen, only be given to people in the earliest stages of the ultimately fatal neurodegenerative condition. The…Read more…Read More